NT5E and colorectal cancer: High CD73 expression was associated with a worse outcome in RAS‐MAPKi‐treated patients with colorectal cancer (CRC), indicating that combined anti‐CD73 and MAPKi treatment could be beneficial for patients with CRC resistant to MAPKi therapy.